Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06912646 · ClinicalTrials.gov registry record · NA

Clinical Efficacy of the Erchonia EVRL for Providing Temporary Relief of Idiopathic Peripheral Neuropathy Foot Pain

A NA study of Neuropathy and Neuropathy;Peripheral, sponsored by Erchonia Corporation.

Recruiting
Registry status
NA
Development phase
32
Enrollment target
1
Study location

NCT06912646 is a NA study of Neuropathy and Neuropathy;Peripheral that is actively recruiting participants, run by Erchonia Corporation. The registered enrollment target is 32 participants, below the 185-participant average among 22 other Neuropathy trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06912646, a NA study of Neuropathy and Neuropathy;Peripheral, is actively recruiting participants, sponsored by Erchonia Corporation.

RECRUITING
Registry status
NA
Development phase
32 participants
Enrollment target
1
Study location

Study Summary

The purpose of this clinical study is to determine the effectiveness of the Erchonia® EVRL™, manufactured by Erchonia Corporation (the Company), in providing prescription home use application for temporary relief of idiopathic neuropathy foot pain in individuals diagnosed with idiopathic neuropathy by a suitably qualified and licensed health professional.

Interventions

  • DEVICE Erchonia® EVRL™

Study Locations (1)

Florida

  • Franco & Co - Miramar

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2025-05-01
Est. Completion 2027-06-16
Phase NA

Sponsor

Erchonia Corporation

34 total trials

What the Registry Record Tells You About NCT06912646

The ClinicalTrials.gov registry entry for NCT06912646 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 185-participant average among 22 other Neuropathy trials with a reported enrollment target (83% lower). The listed sponsor is Erchonia Corporation, which has 34 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Neuropathy appearing as the primary indexed condition, and to 1 intervention - of which Erchonia® EVRL™ is the first listed.

NCT06912646 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT06912646 about?

NCT06912646 is a clinical study titled "Clinical Efficacy of the Erchonia EVRL for Providing Temporary Relief of Idiopathic Peripheral Neuropathy Foot Pain". The purpose of this clinical study is to determine the effectiveness of the Erchonia® EVRL™, manufactured by Erchonia Corporation (the Company), in providing prescription home use application for temporary relief of idiopathic neuropathy foot pain in individuals diagnosed with idiopathic neuropathy ...

What is the current status of trial NCT06912646?

This trial is currently recruiting. It is a NA study. The enrollment target is 32 participants. The study started on 2025-05-01. Estimated completion is 2027-06-16.

What conditions does trial NCT06912646 study?

This clinical trial studies the following conditions: Neuropathy, Neuropathy;Peripheral.

What interventions are being tested in trial NCT06912646?

The interventions under investigation include: Erchonia® EVRL™ (DEVICE).

Who is sponsoring clinical trial NCT06912646?

This trial is sponsored by Erchonia Corporation, which has 34 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06912646 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Neuropathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.